Seres Therapeutics Inc (NASDAQ:MCRB) shares, rose in value on Wednesday, April 16, with the stock price down by -13.44% to the previous day’s close as strong demand from buyers drove the stock to $0.40.
Actively observing the price movement in the last trading, the stock closed the session at $0.46, falling within a range of $0.36 and $0.49. The value of beta (5-year monthly) was 2.53. Referring to stock’s 52-week performance, its high was $1.53, and the low was $0.46. On the whole, MCRB has fluctuated by -46.44% over the past month.
With the market capitalization of Seres Therapeutics Inc currently standing at about $69.72 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 10M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that MCRB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of MCRB currently trading nearly -37.42% and -43.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.76, while the 7-day volatility ratio is showing 20.39% which for the 30-day chart, stands at 11.21%. Furthermore, Seres Therapeutics Inc (MCRB)’s beta value is 2.94, and its average true range (ATR) is 0.08.
A comparison of Seres Therapeutics Inc (MCRB) with its peers suggests the former has fared considerably weaker in the market. MCRB showed an intraday change of -13.44% in last session, and over the past year, it shrunk by -35.28%%.
Data on historical trading for Seres Therapeutics Inc (NASDAQ:MCRB) indicates that the trading volumes over the past 10 days have averaged 1.73 and over the past 3 months, they’ve averaged 1.29 million. According to company’s latest data on outstanding shares, there are 173.01 million shares outstanding.
Nearly 26.90% of Seres Therapeutics Inc’s shares belong to company insiders and institutional investors own 22.93% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.01 million shares as on 2025-03-31, resulting in a short ratio of 18.65. According to the data, the short interest in Seres Therapeutics Inc (MCRB) stood at 1496.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 17.23 million. The stock has fallen by -51.88% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MCRB stock heading into the next quarter.
